Clinical advances in later-line therapy for metastatic or refractory colorectal cancer

doi:10.3748/wjg.123996

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 33, Issue 2

This Article

(2)

(0)

(95)

Peer-Review Report of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jan 14, 2027; 33(2): 123996
Published online Jan 14, 2027. doi: 10.3748/wjg.123996

Full Size Figure Download Figure

Figure 1 Challenges in treatment after first-line failure. BRAF: B-Raf proto-oncogene; CEA: Carcinoembryonic antigen; EGFR: Epidermal growth factor receptor; HER2: Human epidermal growth factor receptor 2; MET: Mesenchymal–epithelial transition factor; MSS: Microsatellite-stable; pMMR: Proficient mismatch repair; PS: Performance status; RAS: Rat sarcoma.

Citation: Ma L, Liu X, Zhang Y, Luo Y. Clinical advances in later-line therapy for metastatic or refractory colorectal cancer. World J Gastroenterol 2027; 33(2): 123996
URL: https://www.wjgnet.com/1007-9327/full/v33/i2/123996.htm
DOI: https://dx.doi.org/10.3748/wjg.123996

Ma L, Liu X, Zhang Y, Luo Y. Clinical advances in later-line therapy for metastatic or refractory colorectal cancer. World J Gastroenterol 2027; 33(2): 123996 [DOI: 10.3748/wjg.123996]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.